

Supplementary Table 9. Subgroup analyses in patients with prostate cancer in valsartan new users according to age

Age (yr)		Eventually NDMA-unexposed	NDMA-exposed	Age NDMA interaction term	
		aHR (95% CI)	aHR (95% CI)	Wald χ^2	p value
Before PSM	≤ 65	0.979 (0.929–1.032)	1.110 (1.063–1.160)	2.080	0.353
	> 65	1.076 (1.011–1.145)	1.166 (1.108–1.226)		
1:1 PSM	≤ 65	-	1.124 (1.031–1.226)	0.310	0.578
	> 65	-	1.162 (1.044–1.293)		
1:1:1 PSM	≤ 65	1.065 (0.960–1.181)	1.176 (1.070–1.294)	0.433	0.805
	> 65	1.037 (0.904–1.190)	1.208 (1.068–1.368)		

NDMA, N-nitrosodimethylamine; aHR, adjusted hazard ratio; CI, confidence interval; PSM, propensity score matching.
 This analysis was performed excluding patients with events with 2 years after the first observed valsartan prescription.